| tanimilast (CHF6001) / Chiesi |
PILASTER, NCT04636801 / 2020-003666-40: A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis |
|
|
| Recruiting | 3 | 3435 | Europe, US, RoW | Experimental: CHF6001 1600µg, Experimental: CHF6001 3200µg, Placebo | Chiesi Farmaceutici S.p.A. | Chronic Obstructive Pulmonary Disease | 06/25 | 06/25 | | |
PILLAR, NCT04636814 / 2020-003648-97: A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. |
|
|
| Recruiting | 3 | 3980 | Europe, US, RoW | CHF6001 1600µg, CHF6001 3200µg, Placebo, Roflumilast | Chiesi Farmaceutici S.p.A., Chiesi Farmaceutici S.p.A. | Chronic Obstructive Pulmonary Disease | 09/27 | 09/27 | | |
TANGO, NCT06029595: Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy |
|
|
| Recruiting | 2 | 464 | Europe, RoW | Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo | Chiesi Farmaceutici S.p.A. | Uncontrolled Asthma | 12/25 | 12/25 | | |
NCT05373953: Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects |
|
|
| Completed | 1 | 44 | Europe | CHF6001 | Chiesi Farmaceutici S.p.A. | Chronic Obstructive Pulmonary Disease | 11/22 | 11/22 | | |
NCT06395610: Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers |
|
|
| Completed | 1 | 24 | Europe | CHF6001 DPI, Erythromycin | Chiesi Farmaceutici S.p.A. | Chronic Obstructive Pulmonary Disease | 06/24 | 06/24 | | |